A Phase II Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Combination Lenalidomide (Revlimid) With Rituximab in Subjects With Relapsed or Refractory Diffuse Large b Cell Non-Hodgkin's Lymphoma.
Phase of Trial: Phase II
Latest Information Update: 18 Oct 2016
Price : $35 *
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 30 Sep 2013 New trial record
- 01 Sep 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.